Renal cell carcinoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-HPRC-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB — v0.2-B confirmed-carrier surveillance pathway (HPRC / MET). Sibling — IND-HPRC-CARRIER-INTENSIFIED (aggressive plan_track).

Used By

Indication

IND-HPRC-CARRIER-INTENSIFIED - IND-HPRC-CARRIER-INTENSIFIED

Red flag

RF-HPRC-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in the MET proto-oncogene — Her...